The National Science and Technology Council (NSTC) approved on July 2, 2025, six investment projects across various science parks in the Hsinchu region, totaling NT$1.83 billion (US$63.3 million). Additionally, five project terminations and nine capital increase cases were filed for record, marking a total of NT$2.77 billion in new capital investment.
Advanced packaging and testing capabilities
The newly approved projects include a Hsinchu Science Park branch of Winstek Semiconductor, with an investment of NT$800 million. This project will focus on the development of 2.5D/3D wafer and IC testing technologies for use in AI computing, automotive electronics, IoT, and 5G chips, offering crucial packaging and testing technologies for future AI and high-performance computing products.
Winstek specializes in heterogeneous integration and high-density packaging applications, including critical processes such as TSV (through-silicon via), interposer design, and packaging reliability optimization. The company has demonstrated its expertise in customization and system integration through collaborations with material and equipment suppliers. Its TSV technology can integrate logic and memory chips with other components, while its advanced testing solutions support high-speed, high-current, high-LVM, and 12-inch wafer specifications, effectively shortening customer lead time and reducing costs.
Next-generation display technology
Rayleigh Vision Intelligence will also invest NT$500 million at Hsinchu Science Park for developing micro LED technology, using AI-driven micro LED cross-disciplinary processes to improve mass production capacity for applications including AR/VR headsets and other wearables. The company currently focuses on next-generation display technology, with the potential to expand into silicon photonics high-speed communication components.
Laser modules for data centers
Optoway Technology's NT$100 million investment at Hsinchu Science Park will focus on high-speed laser modules, high-power lasers, and high-speed electro-absorption modulated lasers (EML), which are key components in data centers and AI computing networks. As the sole Taiwanese company currently capable of developing and manufacturing both front-end laser chips and back-end high-speed laser modules, Optoway's strength lies in its vertical integration ability to optimize performance and delivery schedules to suit clients' needs. The company is a leader in fostering talent and development in Taiwan's laser and communications sectors.
Smart optical manufacturing
Apexlens will invest NT$210 million at Hsinchu Science Park to build a smart automated factory featuring ultra-precision optical mold fabrication and silicone hydrogel lens injection molding. The company will also invest in developing contact lenses with vision correction or medical functions. Apexlens's main products are high-oxygen-permeability silicone hydrogel contact lenses, with a range of daily and monthly colored and blue silicone hydrogel lenses for the consumer market, which have received regulatory approval from Taiwan's TFDA, Japan's PMDA, the EU's MDD, Singapore's HSA, and Malaysia's MDA. The company holds key technologies in the integration of biomedical materials, precision optics, and automation, with proprietary innovations including high-oxygen-permeability hydrophilic polymers, multifunctional contact lenses, and myopia control lenses. Its presence in the science park is expected to further boost the development of Taiwan's tertiary medical industry.
Biomedical innovations
Phalanx Biotech Group will invest NT$120 million at the Hsinchu Biomedical Science Park for the production of high-density gene chips such as the CytoOneArray V4.0, hereditary hearing and vision impairment gene chips, and polygenic risk score (PRS) chips, with a focus on maternal and child health and preventive medicine. The company aims to enhance gene testing sensitivity and accuracy through breakthrough detection technologies and analytics platforms.
Expercy Medical will also invest NT$100 million at the Hsinchu Biomedical Science Park. The company's main products are DividPro, a resorbable anti-adhesion and guided tissue regeneration membrane, and a spinal anti-adhesion gel for use in minimally invasive surgeries. The newly developed multifunctional thermoresponsive hydrogel features a breakthrough formulation that is liquid at room temperature but quickly forms a stable gel in the body after injection, effectively reducing spinal post-operative adhesion risk and severity, and offering improved usability over existing products. Furthermore, the company has plans to integrate drug delivery and release systems as it expands into other clinical applications.
Article edited by Jerry Chen
